

APC anti-human CD166

Catalog # / Size: 2319530 / 100 tests
2319525 / 25 tests

Clone: 3A6

Isotype: Mouse IgG1, κ

Immunogen: Cultured human thymic epithelial cells


Reactivity: Human, Non-human primate, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Workshop Number: HCDM listed

Concentration: Lot-specific



PHA-stimulated (3 day) human peripheral blood lymphocytes were stained with CD166 (clone 3a6) APC (filled histogram) or mouse IgG1, κ APC isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of paraffin-embedded tissue sections and immunofluorescence.¹

Application References: 1. Pretzel D, *et al.* 2011. *Arthritis Res. Ther.* 13:R64. (IHC, IF, FC)

Description: CD166, also known as the CD6 ligand or the Activated Leukocyte Cell Adhesion Molecule (ALCAM), is a 100-105 kD transmembrane glycoprotein. It belongs to the Ig superfamily of proteins and expressed on activated T cells, activated monocytes, epithelial cells, fibroblasts, and neurons. CD166 plays an important role in mediating adhesion interactions between thymic epithelial cells and CD6+ cells during intrathymic T cell development. Recently CD166 has also been used as a potential cancer stem cell marker. The antibody reacts with human activated leukocyte cell adhesion molecule (ALCAM).

Antigen References:

1. Aruffo A, *et al.* 1997. *Immunol Today.* 18(10):498
2. Patel DD, *et al.* 1995. *J. Exp. Med.* 181:2213
3. Bowen MA, *et al.* 1995. *J. Exp. Med.* 181:1563
4. Horst D, *et al.* 2009. *Cancer Invest.* 22:1